Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

STI-6129

Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor

Trial Locations (3)

NYU Lagone Health, New York

Columbia University Medical Center, New York

Gabrail Cancer Center, Canton

All Listed Sponsors

lead

Sorrento Therapeutics, Inc.

INDUSTRY